**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 52613

**Manuscript Type:** CASE REPORT

**Collision tumor of squamous cell carcinoma and neuroendocrine carcinoma in the head and neck: A case report**

Wu SH *et al*. A case of collision carcinoma

Shi-Hai Wu, Bao-Zhu Zhang, Ling Han

**Shi-Hai Wu,** Department of Radiation Oncology, the Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital, Shenzhen 518020, Guangdong Province, China

**Bao-Zhu Zhang,** Department of Oncology, The People’s Hospital of Baoan, Shenzhen, The Affiliated Baoan Hospital of Southern Medical University, Shenzhen 518020, Guangdong Province, China

**Ling Han,** Department of Otorhinolaryngology, the Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital, Shenzhen 518020, Guangdong Province, China

**Author contributions:** Wu SH and Zhang BZ contributed equally to this research; Wu SH collected the patient’s clinical data as the patient’s radiologist; Zhang BZ reviewed the literature and contributed to manuscript drafting; Han L interpreted the imaging findings and was responsible for the revision of the manuscript; all authors issued final approval for the version to be submitted.

**Supported by** National Natural Science Foundation of China, No. 81802732.

**Corresponding author: Ling Han, MD, Doctor,** Department of Otorhinolaryngology, the Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital, 1017 Dongmen North Road, Shenzhen 518020, Guangdong Province, China. hanlingsunny@163.com

**Received:** January 20, 2020

**Revised:** April 24, 2020

**Accepted:** May 23, 2020

**Published online:**

**Abstract**

BACKGROUND

There are many disputes about the definition, diagnosis, therapy, and prognosis of collision tumors.

CASE SUMMARY

We describe a rare patient with a collision tumor consisting of neuroendocrine carcinoma (NEC) and squamous cell carcinoma (SCC) in the nasal cavity and paranasal sinus. She received operation, concurrent chemoradiotherapy, and then two cycles of palliative chemotherapy. Follow-up at 12 mo after diagnosis showed that this patient experienced a complete response with no signs of recurrence or metastasis. A literature review of previous 26 cases diagnosed with collision tumor of NEC and SCC in the head and neck was also undertaken.

CONCLUSION

It is challenging to manage collision tumors because there are two morphologically and etiologically distinct tumors. Well-designed multimodality therapy including surgery and chemoradiotherapy might lead to a long survival in these patients.

**Key words:** Collision tumor; Squamous carcinoma; Neuroendocrine carcinoma; Chemoradiotherapy; head and neck; Case report

Wu SH, Zhang BZ, Han L. Collision tumor of squamous cell carcinoma and neuroendocrine carcinoma in the head and neck: A case report. *World J Clin Cases* 2020; In press

**Core tip:** It is rare to see collision carcinoma composed of squamous carcinoma and neuroendocrine carcinoma (NEC) in the head and neck region. In this paper, we present a case of squamous cell carcinoma and NEC colliding in the nasal cavity and paranasal sinus. Besides, 26 cases of collision carcinoma in the head and neck were also reviewed to further comprehend the multimodality therapy of collision carcinoma.

**INTRODUCTION**

Collision tumor of squamous cell carcinoma (SCC) and neuroendocrine carcinoma (NEC) in the head and neck appears rare[[1](#_ENREF_1)]. This type of tumor in the nasal cavity and paranasal sinus is an even less likely occurrence[[2](#_ENREF_2)]. A multidisciplinary approach including surgery, chemotherapy, and radiotherapy should be carefully designed once the diagnosis is confirmed. The real challenge is how to treat two synchronous malignancies. Here, we present a case of SCC and NEC colliding in the nasal cavity and paranasal sinus to promote the understanding of collision carcinoma.

**CASE PRESENTATION**

***Chief complaints***

A 47-year-old female patient presented with frequent intermittent bleeding in the right nasal cavity for 6 mo.

***History of present illness***

The symptom of nosebleed was exacerbated with the passage of time. The patient had no fever, headache, chest tightness, or shortness of breath.

***History of past illness***

The patient used to be in good health. No history of major past illnesses was found.

***Personal and family history***

No relevant personal or family history was found.

***Physical examination***

No obvious abnormalities were found in physical examination.

***Laboratory examinations***

No obvious abnormalities were found in laboratory examinations.

***Imaging examinations***

A computed tomography (CT) scan revealed a 4.1 cm × 2.85 cm × 4.3 cm heterogenous mass of the right nasal and paranasal region, which invaded the nasal septum, right inferior middle turbinate, and right lateral wall of maxillary sinus bone, expanded to the right orbital base, and compressed the right internal rectus muscle and the right optic nerve (Figure 1). The neck and abdominal ultrasound showed no metastasis signs.

**FINAL DIAGNOSIS**

Biopsy pathology of nasal mass specimen revealed poorly differentiated SCC with necrosis. Postoperative pathology of the specimen revealed poorly differentiated SCC with neuroendocrine carcinoma as a collision tumor (Figure 2A).CK5/6 was diffusely positive in the squamous differentiationareaand negative in neuroendocrine differentiation cells (Figure 2B). P40 was also diffusely positive in the squamous differentiationarea (Figure 2C). CD56 was positive in neuroendocrine components (Figure 2D and E). Chromogranin A and synaptophysin expression was negative (Figure 2E and F).

**TREATMENT**

She received operation in August 2018. A CT scan after the surgery revealed residual lesions in the primary tumor region (Figure 3A and B). Then concurrent chemoradiotherapy was performed with radiotherapy 68.0 Gy and chemotherapy of lobaplatin and VP-16 for four cycles. The chemotherapy regimen was lobaplatin (55 mg, day 1) and VP-16 (100 mg/m2, day 1-3). Follow-up at 3 mo after completion of the full course of treatment showed that the patient experienced a complete response (Figure 3A and B).

**OUTCOME AND FOLLOW-UP**

Positron emission tomography-CT taken in August 2019 (12 mo after diagnosis) revealed no signs of recurrence or metastasis (Figure 3C).

**DISCUSSION**

Different terms, including collision/mixed/composite/combined tumor, have been employed to describe tumor consisting of two malignant components. The more troublesome is that the definition of collision tumor has been a matter of debate for years. In 2000, the World Health Organization (WHO) classifications of tumors of endocrine organs suggested that collision tumors are those in which either component occupies at least 30% of the tumor tissues[[3](#_ENREF_3),[4](#_ENREF_4)]. However, it might be an arbitrary criterion since the 30% cutoff has not been proven by reliable clinical data. The more malignant component in collision tumor, even if its share is less than 30%, tends to alter the biological behaviors. Furthermore, in the WHO classification of thyroid and lung tumors[[5](#_ENREF_5),[6](#_ENREF_6)], mixed NEC and non-NEC tumors were not defined by a minimum percentage. We agree to the proposition of Yu *et al*[[7](#_ENREF_7)] that collision carcinoma should meet the following conditions: Two malignant neoplasms of different pathological types derive simultaneously from the same location of human body and appear like a mass to the naked eye, with no evidence that one neoplasm migrates from the other.

According to our definition of collision tumor, we reviewed 26 well-documented cases of collision tumor of NEC and SCC in the head and neck from 1978 to 2019 (key words: Collision or mixed or composite or combined carcinoma, and the head and neck). Combining the data with our patient, the resulting group of 27 patients is large enough to allow some meaningful analysis. Of all cases, 23 were male and 4 were female. The sex ratio of men to women is 5.75:1, which displays a significant difference. The mean age of the 25 patients was 58.37 years (range: 32-83 years). Their clinical pathological features, treatments, and outcomes are summarized in Table 1. As to tumor sites, 20 (74.1%) originated from the larynx, 4 (14.8%) from the nasal and paranasal cavity, 1 from the palatine tonsil, and 1 from the soft palate. Fourteen (55.5%) patients were heavy smokers, which keeps consistent with the association between cigarette usage and head-neck cancer. Of all cases, 7 received surgery (S) alone; 7 received chemotherapy (C) and radiotherapy (R); 6 received S + R + C; 5 received S + R; 1 received S + C; and 1 received no treatment for high performance status (grade 3). Follow-up information was available for 23 patients (Table 1). Eight patients died of diseases (tumor) from 3.5 to 39 mo after diagnosis (mean survival, 24.1 mo), and 8 were clinically disease-free, from 6 to 60 mo (mean survival: 18.9 mo) following diagnosis. Seven patients were living with unresectable tumor, from 12 to 39 mo (mean survival, 28.8 mo), after diagnosis. There were only 2 patients who developed local relapse, and coincidentally, both of them received C + R treatment but no surgery. Four patients had recurrent regional lymph nodes metastases, 7 developed remote metastasis, including 3 affecting the bone, 1 lung, 1 lung and bone, 1 bone and liver, and 1 right breast mass.

One difficulty existing in collision tumor is to establish accurate preoperative diagnosis. To obtain two malignant neoplasms by single biopsy is like to kill two birds with one stone. A definite diagnosis most depends on careful microscopic observation of surgical specimens, especially with the application of immunohistochemistry. Another problem is that the outcome of collision tumor of SCC and NEC appear very poor. As far as we know, there have been two reports of collision carcinoma involving NEC and SCC in the nasal and paranasal region. However, it is the first case who achieved a complete response. Ferlito *et al*[[8](#_ENREF_8)] raised the point that radical surgery takes little effect in improving local tumor control of collision tumor of the larynx. Besides, laryngectomy will result in voice loss and control only the primary lesion. Therefore, a combination of systematic chemotherapy and radiotherapy is recommended for small cell carcinoma. National Comprehensive Cancer Network Guidelines of Neuroendocrine Tumors (version 2015) suggest that patients with locoregional unresectable neuroendocrine tumors receive R + C; moreover, therapeutic manner of small cell carcinoma of the lung, which combined R with systemic chemotherapy, is worth learning.

Due to the rarity of collision carcinoma of NEC and SCC in the head and neck, the treatments should be carefully designed for two different malignancies. Our case indicated that high attention should be paid to the malignant degree of both components and individual characteristics, and certain patients may benefit from postoperative concurrent radiotherapy and chemotherapy.

**CONCLUSION**

In a word, we have described a case of collision carcinoma of SCC and NEC in the nasal cavity and paranasal sinus. The existed literature of collision tumor in the head and neck region has been analyzed to understand this disease. Treatments including surgery and chemoradiotherapy may lead to a good survival for patients. More cases of collision carcinoma need to be reported and summarized.

**REFERENCES**

1 **Coca-Pelaz A**, Triantafyllou A, Devaney KO, Rinaldo A, Takes RP, Ferlito A. Collision tumors of the larynx: A critical review. *Am J Otolaryngol* 2016; **37**: 365-368 [PMID: 27105979 DOI: 10.1016/j.amjoto.2016.02.010]

2 **Barham HP**, Said S, Ramakrishnan VR. Colliding tumor of the paranasal sinus. *Allergy Rhinol (Providence)* 2013; **4**: e13-e16 [PMID: 23772319 DOI: 10.2500/ar.2013.4.0040]

3 **Solcia E,** Kloppel G, Sobin LH. Histological typing of endocrine tumours. WHO International Histological Classification of Tumours, 2nd edition. Berlin: Springer, 2000

4 **Volante M**, Rindi G, Papotti M. The grey zone between pure (neuro)endocrine and non-(neuro)endocrine tumours: a comment on concepts and classification of mixed exocrine-endocrine neoplasms. *Virchows Arch* 2006; **449**: 499-506 [PMID: 17033797 DOI: 10.1007/s00428-006-0306-2]

5 **DeLellis RA,** Lloyd RA, Heitz PU, Eng C. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press, 2004

6 **Travis WD,** Brambilla E, Burke AP, Marx A, Nicholson AG. World Health Organization Classification of Tumours. Pathology Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2015

7 **Yu Q**, Chen YL, Zhou SH, Chen Z, Bao YY, Yang HJ, Yao HT, Ruan LX. Collision carcinoma of squamous cell carcinoma and small cell neuroendocrine carcinoma of the larynx: A case report and review of the literature. *World J Clin Cases* 2019; **7**: 242-252 [PMID: 30705902 DOI: 10.12998/wjcc.v7.i2.242]

8 **Ferlito A**, Recher G, Caruso G. Primary combined small cell carcinoma of the larynx. *Am J Otolaryngol* 1985; **6**: 302-308 [PMID: 2994505 DOI: 10.1016/s0196-0709(85)80059-4]

9 **Eusebi V**, Betts CM, Giangaspero F. Primary oat-cell carcinoma of the larynx. *Virchows Arch A Pathol Anat Histol* 1978; **380**: 349-354 [PMID: 214939 DOI: 10.1007/bf00431320]

10 **Gnepp DR**, Ferlito A, Hyams V. Primary anaplastic small cell (oat cell) carcinoma of the larynx. Review of the literature and report of 18 cases. *Cancer* 1983; **51**: 1731-1745 [PMID: 6299507 DOI: 10.1002/1097-0142(19830501)51:9<1731::aid-cncr2820510929>3.0.co;2-6]

11 **Mills SE**, Cooper PH, Garland TA, Johns ME. Small cell undifferentiated carcinoma of the larynx. Report of two patients and review of 13 additional cases. *Cancer* 1983; **51**: 116-120 [PMID: 6295589 DOI: 10.1002/1097-0142(19830101)51:1<116::aid-cncr2820510123>3.0.co;2-a]

12 **Chen DA**, Mandell-Brown M, Moore SF, Johnson JT. "Composite" tumor--mixed squamous cell and small-cell anaplastic carcinoma of the larynx. *Otolaryngol Head Neck Surg* 1986; **95**: 99-103 [PMID: 3033580 DOI: 10.1177/019459988609500119]

13 **Cosby WN**, Babin RW. Simultaneous oat cell and squamous cell carcinoma of the larynx. *Mil Med* 1988; **153**: 196-198 [PMID: 2838769 DOI: 10.1093/milmed/153.4.196]

14 **Gianoli GJ**, Butcher RB, Martin EJ 3rd. Composite tumor of the larynx. *Ear Nose Throat J* 1992; **71**: 81-82, 85-87 [PMID: 1315242]

15 **Yücel OT**, Sökmensüer C, Gedikoglu G, Ayas K. Combined small cell and squamous cell carcinoma of the larynx: short communication. *Tumori* 2000; **86**: 434-436 [PMID: 11130578 DOI: 10.1177/030089160008600515]

16 **Jaiswal VR**, Hoang MP. Primary combined squamous and small cell carcinoma of the larynx: a case report and review of the literature. *Arch Pathol Lab Med* 2004; **128**: 1279-1282 [PMID: 15504064 DOI: 10.1043/1543-2165(2004)128<1279:PCSASC>2.0.CO;2]

17 **Barbeaux A**, Duck L, Weynand B, Desuter G, Hamoir M, Gregoire V, Baurain JF, Machiels JP. Primary combined squamous and small cell carcinoma of the larynx: Report of two cases and discussion of treatment modalities. *Eur Arch Otorhinolaryngol* 2006; **263**: 786-790 [PMID: 16718502 DOI: 10.1007/s00405-006-0060-8]

18 **Aggarwal G**, Jackson L, Sharma S. Primary combined small cell carcinoma of larynx with lateralized histologic components and corresponding side-specific neck nodal metastasis: report of a unique case and review of literature. *Int J Clin Exp Pathol* 2010; **4**: 111-117 [PMID: 21228933]

19 **Kołodziej P**, Ostasiewicz P, Ziółkowski P. Combined small cell and squamous cell carcinoma of the larynx. *Contemp Oncol (Pozn)* 2012; **16**: 350-352 [PMID: 23788908 DOI: 10.5114/wo.2012.30067]

20 **Kayakabe M**, Takahashi K, Okamiya T, Segawa A, Oyama T, Chikamatsu K. Combined small cell carcinoma of the sinonasal tract associated with syndrome of inappropriate secretion of antidiuretic hormone: A case report. *Oncol Lett* 2014; **7**: 1253-1256 [PMID: 24944702 DOI: 10.3892/ol.2014.1882]

21 **Franchi A**, Rocchetta D, Palomba A, Degli Innocenti DR, Castiglione F, Spinelli G. Primary combined neuroendocrine and squamous cell carcinoma of the maxillary sinus: report of a case with immunohistochemical and molecular characterization. *Head Neck Pathol* 2015; **9**: 107-113 [PMID: 24327102 DOI: 10.1007/s12105-013-0513-5]

22 **Yamagata K**, Terada K, Uchida F, Kanno N, Hasegawa S, Yanagawa T, Bukawa H. A Case of Primary Combined Squamous Cell Carcinoma with Neuroendocrine (Atypical Carcinoid) Tumor in the Floor of the Mouth. *Case Rep Dent* 2016; **2016**: 7532805 [PMID: 28116178 DOI: 10.1155/2016/7532805]

23 **Nakano T**, Motoshita J, Tanaka R, Okabe M, Tamae A, Shiratsuchi H, Yasumatsu R, Nakashima T, Nakagawa T. Primary combined small cell carcinoma and squamous cell carcinoma of the oropharynx with special reference to EGFR status of small cell carcinoma component: Case report and review of the literature. *Auris Nasus Larynx* 2017; **44**: 472-478 [PMID: 27496009 DOI: 10.1016/j.anl.2016.07.011]

24 **Udompatanakorn C,** Yada N, Ishikawa A, Miyamoto I, Sato Y, Matsuo K. Primary Neuroendocrine Carcinoma Combined with Squamous Cell Carcinoma of the Soft Palate: A Case Report and Review of Literature. *Open J Stomatol* 2018; **8**: 90-99 [DOI: 10.4236/ojst.2018.83008]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** January 20, 2020

**First decision:** April 1, 2020

**Article in press:**

**Specialty type:** Medicine, Research and Experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0


**P-Reviewer:** Huang AHC, Tsuji Y **S-Editor:** Dou Y **L-Editor:** Wang TQ **E-Editor:**

**Figure Legends**

**Figure 1 Images before surgery showing a mass in the nasal cavity and paranasal region.**

**图片包含 游戏机, 地毯

描述已自动生成Figure 2 Immunohistochemical images.** A: Hematoxylin and eosin (HE) staining showed typical squamous and neuroendocrine differentiation areas of the neoplasm; B: CK5/6 was diffusely positive in the squamous differentiation area and negative in neuroendocrine differentiation cells; C: P40 was diffusely positive in the squamous differentiation area; D: CD56 was positive in neuroendocrine components; E: Chromogranin A expression was negative; F: Synaptophysin expression was negative. Original magnification, × 200.

**Figure 3 The patient has a complete response after chemoradiotherapy.** A: Images after surgery showing postoperative residual lesions (white arrows); B: Images after surgery showing that a complete response was achieved; C: The latest positron emission tomography-computed tomography showing no signs of recurrence or metastasis.

**Table 1 Summary of 27 cases of collision carcinoma of neuroendocrine carcinoma and squamous cell carcinoma in the head and neck**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Year** | **Sex/age** | **Site** | **Smoke** | **Treatment** | **Follow-up** | **Recurrence type** |
| Eusebi *et al*[9] | 1978 | M/63 | Larynx | Yes | S | DOD (24) | Regional |
| Gnepp *et al*[10] | 1983 | M/57 | Larynx | Yes | S + R | DOD (3.5) | Bone |
| Gnepp *et al*[10] | 1983 | M/63 | Larynx | Yes | S | DOD (24) | Regional |
| Mills *et al*[11] | 1983 | M/49 | Larynx | Yes | S + R | AFD (6) |  |
| Ferlito *et al*[8] | 1985 | M/57 | Larynx | Yes | S + R | DOD (3.5) | Bone |
| Ferlito *et al*[8] | 1985 | M/56 | Larynx | Yes | C + R | AFD (60) |  |
| Ferlito *et al*[8] | 1985 | M/45 | Larynx | Yes | C + R | DOD (21) |  |
| Ferlito *et al*[8] | 1985 | M/47 | Larynx | Yes | C + R | AWD (39) | Lung |
| Ferlito *et al*[8] | 1985 | M/54 | Larynx | Yes | S | AFD (24) |  |
| Chen *et al*[12] | 1986 | M/55 | Larynx | No | S + R + C | DOD (9) | Bone, lung |
| Chen *et al*[12] | 1986 | M/56 | Larynx | No | S + C | AWD (13) | Regional |
| Cosby *et al*[13] | 1988 | M/56 | Larynx | Yes | S + R + C | uk |  |
| Gianoli *et al*[14] | 1992 | M/83 | Larynx | Yes | S | AFD (8) |  |
| Yücel *et al*[15] | 2000 | M/32 | Larynx | No | S + R + C | AWD (12) | Regional |
| Jaiswal *et al*[16] | 2004 | M/41 | Larynx | Yes | C + R | AFD (8) |  |
| Barbeaux *et al*[17] | 2006 | M/61 | Larynx | No | C + R | AWD (44) | Local |
| Barbeaux *et al*[17] | 2006 | F/54 | Larynx | No | C + R | AWD (36) | Breast |
| Aggarwal *et al*[18] | 2010 | M/59 | Larynx | Yes | S + R | uk |  |
| Kołodziej *et al*[19] | 2010 | M/59 | Larynx | No | S | uk |  |
| Barham *et al*[2] | 2013 | F/83 | Nasal cavity | No | S | AWD (13) | Bone |
| Kayakabe *et al*[20] | 2014 | F/80 | Nasal cavity | No | None | DOD (5) |  |
| Franchi *et al*[21] | 2015 | M/75 | Maxillary sinus | Yes | S + R | AFD (20) |  |
| Yamagata *et al*[22] | 2016 | M/65 | The floor of the mouth | No | C + R | AWD (12) | Local |
|
| Nakano *et al*[23] | 2017 | M/59 | Palatine tonsil | Yes | S + R + C | DOD (12) | Liver, bone |
| Udompatanakorn *et al*[24] | 2018 | M/59 | Soft palate | No | S | uk |  |
| Yu *et al*[7] | 2019 | M/61 | Larynx | No | S + R + C | AFD (13) |  |
| Our case | 2019 | F/47 | Nasal cavity and paranasal sinus | No | S + R + C | AFD (12) |  |

M: Male; F: Female; R: Radiotherapy; S: Surgery; C: Chemotherapy; R: Radiotherapy; DOD: Died of disease; AWD: Alive with disease; AFD: Alive free of disease; uk: Unknown.